Medichem, S.A.

medichem.es

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) , Active Pharmaceutical Ingredients (API) and HPAPI. From its headquarters in Barcelona, Spain, Medichem has grown into one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry. Made up of a workforce of 450 talented individuals located in Spain (HQ), the USA, Malta and China, Medichem serves 60 countries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

CHARLES RIVER AND VALENCE DISCOVERY DECLARE STRATEGIC PARTNERSHIP TO PROVIDE AI-ENABLED DRUG DESIGN CAPABILITIES TO CLIENTS

Valence Discovery, Charles River | April 08, 2021

news image

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug ...

Read More

MEDTECH, INDUSTRIAL IMPACT

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

news image

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

news image

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

news image

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More
news image

AI

CHARLES RIVER AND VALENCE DISCOVERY DECLARE STRATEGIC PARTNERSHIP TO PROVIDE AI-ENABLED DRUG DESIGN CAPABILITIES TO CLIENTS

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug ...

Read More
news image

MEDTECH, INDUSTRIAL IMPACT

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More
news image

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More
news image

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More